Economic impact of NGS in non small cell lung cancer

Bookmark and Share
Published: 4 Jun 2018
Views: 751
Dr Nathan Pennell - Cleveland Clinic Cancer Center, Cleveland, USA

Dr Pennell speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about findings from a statistical model of testing strategies for lung cancer.

Dr Pennell summarises the 4 assessed strategies, including Next Generation Sequencing to derive all significant biomarkers, implemented in a hypothetical population of 1 million people.

He describes how NGS offers the fastest, most cost-effective means of providing actionable genetic insights, compared to other strategies.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.